Skip to main content
Advertising

Originally published August 5, 2014 at 10:46 AM | Page modified August 5, 2014 at 6:48 PM

  • Share:
             
  • Comments
  • Print

Juno Therapeutics snags $134M

Juno Therapeutics, the Seattle biotechnology startup unveiled in December by leading cancer scientists here and in New York, has raised $300 million in less than a year.


Seattle Times business reporter

advertising

Juno Therapeutics, the Seattle biotechnology startup unveiled in December by leading cancer scientists here and in New York, has announced another $134 million in financing, bringing its total funding to $300 million in less than a year.

The new funding comes from 10 public mutual funds and health-care-related funds, as well as all the major previous investors.

“The real goal behind this round — beyond it being a financing event — is to forge long-term relationships with investors,” Hans Bishop, CEO of Juno, said in an interview. “They are not just investing in clinical development, but in scientific questions that we really believe will allow us to make better products in the future.”

Juno is working to develop curative immunotherapy treatments for a variety of high-risk cancers. Its approach is to bolster a patient’s cancer-fighting immune responses by taking T-cells, which fight infections and cancers in the body, out of his or her body and reprogramming them to include receptors to help recognize and kill cancer cells.

With the additional funding, Bishop says the company will continue advancing its product pipelines.

Three different clinical trials for blood cancers are currently running, and Bishop said he hopes to start the first trials with solid organ tumors next year. The company will also continue to invest in basic research and manufacturing technologies that will allow it to make its products.

The company, with offices in South Lake Union, was formed in partnership with Fred Hutchinson Cancer Research Center, New York’s Memorial Sloan-Kettering Cancer Center, and Seattle Children’s Research institute. It isn’t saying how large a work force it has built with its fat bankroll.

Juno’s initial $120 million startup financing in the fourth quarter of last year was the nation’s largest early-stage venture deal for that quarter, according to a MoneyTree report released in January by PricewaterhouseCoopers and the National Venture Capital Association. Prior to the current round, investors included ARCH Venture Partners, the Alaska Permanent Fund, Bezos Expeditions and Venrock.

The 2013 deal also accounted for nearly 25 percent of all the venture funding received by Washington companies for the quarter. According to MoneyTree reports for the first and second quarters of this year, the company raked in an additional nearly $55 million. Juno reports its total Series A funding as $176 million.

“Those kinds of raisings are fairly unprecedented ... You don’t see companies raise $300 million in under a year,” said Chris Rivera, president and CEO of the Washington Biotechnology and Biomedical Association.

Biotech companies can burn through tens of millions of dollars quickly as they recruit scientists and conduct long, costly testing of products that are years away from potential revenues.

The rule of thumb, said Rivera, is that “When you have the opportunity to raise funding, you should do it.”

Jeff Grabow, the U.S. venture-capital leader at Ernst & Young, a global-accounting and consulting firm, agreed. He also has a name for funding rounds exceeding $50 million — mega rounds.

He calls the current trend in large venture-capital deals a “mega round phenomenon.” He said many mega rounds are associated with tech companies because they are easy to fund upfront, but need more money to scale up later.

Biotechnology companies like Juno, on the other hand, require a lot of capital at all levels for product development and to get a drug to market, he said.

With the resurgence of biotech companies, the market is receptive, he said.

“There is great opportunity to invest in companies like this,” he said. “We haven’t solved a lot of the problems that afflict man — there is still a lot of work to be done on cancer and other debilitating diseases.”

The latest $134 million deal comes five months after Juno brought in Steve Harr as CFO and head of corporate development. He previously spent 12 years at Morgan Stanley and is credited with managing more than $20 billion in financing deals.

Coral Garnick: 206-464-2422 or cgarnick@seattletimes.com. On Twitter @coralgarnick



Want unlimited access to seattletimes.com? Subscribe now!

Also in Business & Technology

News where, when and how you want it

Email Icon

Get ready for 2015

Get ready for 2015

The Seattle Times 12-month wall calendar features hand-picked photos of life in the Pacific Northwest. Order while supplies last!

Advertising

Advertising


Advertising
The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►
The Seattle Times

To keep reading, you need a subscription upgrade.

We hope you have enjoyed your complimentary access. For unlimited seattletimes.com access, please upgrade your digital subscription.

Call customer service at 1.800.542.0820 for assistance with your upgrade or questions about your subscriber status.

The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Activate Subscriber Account ►